Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.
According to a release by Amgen, the approval was issued Dec. 15, and was based on results from the N-Momentum trial, in which treatment with Uplizna (inebilizumab-cdon, Horizon Therapeutics) demonstrated an acceptable safety profile while significantly reducing the risk of an NMOSD attack with only two infusions per year following administration of initial loading doses.
Further data cited in the release showed that 87.6% of